Molecular and clinical investigations in patients with low-renin hypertension

Clinical and Experimental Nephrology

Volumn 13, Issue 1, 2009, Pages 1-8

  MacKenzie, Isla S ^a   Brown, Morris J ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Aldosterone; Hypertension; Low renin hypertension; Renin

Indexed keywords

ALDOSTERONE; ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; LISINOPRIL; MINERALOCORTICOID RECEPTOR; NIFEDIPINE; PLACEBO; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; RENIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADRENERGIC SYSTEM; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ARTERIAL PRESSURE; BLOOD PRESSURE; CLINICAL TRIAL; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; RENOVASCULAR HYPERTENSION; REVIEW; SODIUM BALANCE; VASOCONSTRICTION;

ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIURETICS; DOWN-REGULATION; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; KIDNEY; RENIN; RENIN-ANGIOTENSIN SYSTEM; SODIUM; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME; WATER-ELECTROLYTE BALANCE;

EID: 59449099074     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-008-0071-4     Document Type: Review

References (29)

1. SJ Hood KP Taylor MJ Ashby MJ Brown 2007 The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio Circulation 116 3 268 75
2. S Hood J Cannon R Foo M Brown 2005 Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing Clin Med 5 1 55 60
3. RD Gordon M Stowasser TJ Tunny SA Klemm JC Rutherford 1994 High incidence of primary aldosteronism in 199 patients referred with hypertension Clin Exp Pharmacol Physiol 21 4 315 8
4. PO Lim E Dow G Brennan RT Jung TM MacDonald 2000 High prevalence of primary aldosteronism in the Tayside hypertension clinic population J Hum Hypertens 14 5 311 5
5. TJ Burton G Cope MJ Brown 2007 Expression of the epithelial Na channel and other components of an aldosterone response pathway in human zona glomerulosa cells J Hum Hypertens 21 S4
6. FA Mir MJ Brown 2007 The effect of fludrocortisone on plasma aldosterone levels in healthy volunteers and patients with Conn's syndrome J Hum Hypertens 21 S18
7. O Akizuki A Inayoshi T Kitayama 2008 Blockade of T-type voltage-dependent Ca(2+) channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R Eur J Pharmacol 584 2-3 424 34
8. JA Millar AD Struthers GH Beastall JL Reid 1982 Effect of nifedipine on blood pressure and adrenocortical responses to trophic stimuli in humans J Cardiovasc Pharmacol 4 Suppl 3 S330 4
9. H Vierhapper W Waldhausl 1982 Reduced pressor effect of angiotensin II and of noradrenaline in normal man following the oral administration of the calcium-antagonist nifedipine Eur J Clin Invest 12 3 263 7
10. J Staessen R Fagard P Hespel P Lijnen E Moerman A Amery 1989 Acute calcium entry blockade inhibits the blood pressure but not the hormonal responses to angiotensin II Eur J Clin Pharmacol 36 6 567 73
11. F Pasanisi HL Elliott JL Reid 1985 Vascular and aldosterone responses to angiotensin II in normal humans: effects of nicardipine J Cardiovasc Pharmacol 7 6 1171 5
12. HL Elliott F Pasanisi JL Reid 1985 Effects of nicardipine on aldosterone release and pressor mechanisms Br J Clin Pharmacol 20 Suppl 1 99S 102S
13. JL Nadler W Hsueh R Horton 1985 Therapeutic effect of calcium channel blockade in primary aldosteronism J Clin Endocrinol Metab 60 5 896 9
14. P Mulatero F Rabbia A Milan 2002 Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism Hypertension 40 6 897 902
15. GS Stokes JC Monaghan K Berman M Ryan DJ Campbell 1998 Double-blind crossover study of the interaction between perindopril and amlodipine on blood pressure and hormones related to fluid and electrolyte balance in patients with essential hypertension J Hum Hypertens 12 2 129 34
16. TM Fiad SK Cunningham FJ Hayes TJ McKenna 1997 Effects of nifedipine treatment on the renin-angiotensin-aldosterone axis J Clin Endocrinol Metab 82 2 457 60
17. JD Dietz S Du CW Bolten 2008 A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity Hypertension 51 3 742 8
18. MJ Brown RV Hopper 1999 Calcium-channel blockade can mask the diagnosis of Conn's syndrome Postgrad Med J 75 882 235 6
19. EL Bravo FM Fouad-Tarazi RC Tarazi M Pohl RW Gifford DG Vidt 1988 Clinical implications of primary aldosteronism with resistant hypertension Hypertension 11 2 Pt 2 I207 11
20. GW Liddle T Bledsoe WS Coppage 1966 A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion Trans Assoc Physicians 76 199 213
21. DJ Sutherland JL Ruse JC Laidlaw 1966 Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone Can Med Assoc J 95 22 1109 19
22. PM Stewart JE Corrie CH Shackleton CR Edwards 1988 Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle J Clin Invest 82 1 340 9
23. FH Wilson S Disse-Nicodeme KA Choate 2001 Human hypertension caused by mutations in WNK kinases Science 293 5532 1107 12
24. JEC Dickerson AD Hingorani CR Palmer MJ Brown 1999 Optimization of antihypertensive treatment by crossover rotation of four major classes Lancet 353 2008 13
25. AJ Deary AL Schumann H Murfet SF Haydock RS Foo MJ Brown 2002 Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs J Hypertens 20 4 771 7
26. NICE. CG34: Hypertension (NICE Guideline). London: National Institute for Health and Clinical Excellence (NICE), 2006.
27. B Williams NR Poulter MJ Brown 2004 Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV J Hum Hypertens 18 3 139 85
28. MJ Brown 2007 Renin: friend or foe? Heart 93 9 1026 33
29. MJ Brown CR Palmer A Castaigne 2000 Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) Lancet 356 9227 366 72